List of Excipients in Branded Drug STIMATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
CSL Behring LLC	STIMATE	desmopressin acetate	0053-6871	BENZALKONIUM CHLORIDE
CSL Behring LLC	STIMATE	desmopressin acetate	0053-6871	CITRIC ACID MONOHYDRATE
CSL Behring LLC	STIMATE	desmopressin acetate	0053-6871	SODIUM CHLORIDE

Last updated: August 11, 2026

ecutive summary: Stimate is a desmopressin acetate nasal spray for short-term control of bleeding in hemophilia A and von Willebrand disease. Its commercial value is constrained by product unavailability following Ferring’s 2020 recall for superpotency and dose-content concerns. The strongest opportunity is a redesigned, preservative-controlled nasal product with validated dose uniformity, improved stability, and a regulatory strategy under 505(b)(2) or an abbreviated pathway where eligible. Excipient differentiation alone is unlikely to create durable exclusivity, but excipient-device-process integration can support approval, lifecycle management, and patent protection.

Stimate Excipient Strategy, Patent Position, FDA Status, and Commercial Opportunities

What is Stimate and why does its formulation matter?

Stimate is a prescription nasal spray containing desmopressin acetate at 1.5 mg/mL. Each 0.1 mL spray delivers 150 micrograms of desmopressin acetate. The product is indicated for patients with mild hemophilia A and certain patients with type 1 von Willebrand disease when the patient has demonstrated an appropriate response to desmopressin.[1]

Desmopressin is a potent peptide analog of vasopressin. The nasal formulation must deliver a low-volume, accurately metered dose while maintaining chemical stability and acceptable nasal tolerability. Variability in concentration or delivered volume has direct clinical consequences because excessive desmopressin exposure can cause water retention, hyponatremia, headache, seizures, and other serious adverse events.

Stimate’s commercial problem is therefore closely linked to formulation and manufacturing control. FDA records describe a 2020 recall involving superpotency and inconsistent product performance. Ferring subsequently reported that Stimate was unavailable while manufacturing and quality issues were addressed.[2]

What excipients are used in the Stimate formulation?

The labeled Stimate formulation contains the following inactive ingredients:

Excipient	Primary formulation role
Citric acid	pH adjustment and buffering
Sodium citrate	Buffer capacity and pH control
Sodium chloride	Tonicity adjustment
Benzalkonium chloride	Preservative
Purified water	Vehicle

The product has an acidic buffered aqueous formulation. The citrate system supports pH control, while sodium chloride helps match nasal tolerability and osmotic conditions. Benzalkonium chloride provides antimicrobial preservation for a multidose nasal container.[1][3]

The excipient list is conventional. It does not provide a strong standalone differentiation platform. A competing product could use the same excipients if it demonstrates equivalent quality, safety, performance, and regulatory compliance.

Which excipient creates the most strategic opportunity?

Benzalkonium chloride is the most commercially significant excipient variable. It enables multidose preservation but can create questions involving nasal tolerability, chronic or repeated exposure, mucosal irritation, and compatibility with the container-closure system. Stimate is generally used intermittently, which reduces the relevance of chronic exposure concerns compared with daily nasal therapies. The excipient remains important because the target population includes children and patients who may require repeated treatment over time.

A new product could pursue one of four approaches:

1. Retain benzalkonium chloride and optimize its concentration, preservative efficacy, and container compatibility.
2. Develop a preservative-free unit-dose or single-use nasal presentation.
3. Replace benzalkonium chloride with another preservative, subject to nasal safety and preservative-effectiveness data.
4. Use a multidose device with an integrated antimicrobial or contamination-control design that reduces reliance on conventional preservatives.

The preservative-free option has the clearest commercial positioning but increases packaging cost, filling complexity, waste, and supply-chain requirements.

What formulation improvements could support a Stimate relaunch?

A credible relaunch strategy would focus on dose accuracy and stability rather than on cosmetic excipient changes.

Dose uniformity and spray performance

The product should be evaluated for:

• Delivered-dose uniformity across the container life
• Priming and repriming behavior
• First-dose and last-dose performance
• Spray plume geometry
• Droplet-size distribution
• Orientation sensitivity
• Temperature and humidity effects
• Container residual volume
• Patient-use variability

The 2020 product failure makes delivered-dose control a central commercial differentiator. A new device with better metering, dose counting, tamper evidence, and end-of-life control could command a stronger position than an otherwise similar nasal spray.

Peptide stability

Desmopressin stability can be affected by pH, temperature, adsorption, oxidation, light exposure, and interactions with the pump and container. The development program should test:

• Desmopressin degradation products
• Adsorption to glass, plastic, elastomer, and pump components
• Extractables and leachables
• Preservative concentration over shelf life
• Container-closure integrity
• Agitation and shipping stress
• Freeze-thaw exposure
• In-use stability after opening

A citrate-buffered formulation is a logical starting point because it is already associated with the reference product. A modified buffer or pH range could be commercially useful if it improves stability or tolerability without changing systemic exposure or nasal absorption.

Unit-dose versus multidose delivery

Attribute	Multidose preserved spray	Preservative-free unit dose
Manufacturing cost	Lower per dose at scale	Higher
Convenience	Better for repeat use	Lower
Contamination risk	Managed through preservative and device	Lower after opening
Packaging complexity	Moderate	High
Excipient differentiation	Limited	Stronger
Pediatric usability	Depends on device	Depends on format
Commercial positioning	Broad access and lower cost	Premium safety and tolerability

For episodic bleeding control, unit-dose packaging may be clinically and commercially attractive. It could also support differentiated labeling for patients with preservative intolerance or institutions seeking reduced contamination risk.

What FDA pathway could a new Stimate product use?

A reformulated Stimate product could potentially use several regulatory pathways, depending on the extent of formulation, device, and manufacturing changes.

505(b)(2) pathway

A 505(b)(2) application may be appropriate for a product that relies partly on FDA findings for an approved desmopressin product while introducing a new formulation, device, excipient system, or dosage presentation.[4] This route may be more practical than a fully independent 505(b)(1) application when the sponsor can bridge the new product to existing safety and efficacy information.

A sponsor should expect requirements involving:

• Comparative pharmacokinetics or pharmacodynamics
• Nasal absorption and bioavailability
• Dose proportionality
• Local nasal tolerability
• Device performance
• Clinical response in relevant patients
• Hyponatremia risk management
• Stability and preservative effectiveness

ANDA strategy

An ANDA may be available if the proposed product qualifies as therapeutically equivalent to a suitable reference listed drug and satisfies the applicable sameness requirements for active ingredient, dosage form, strength, route, and performance. A materially different excipient system or device may complicate the ANDA route.

A sponsor seeking preservative-free delivery, a new pump, or a materially different formulation may find 505(b)(2) more suitable than an ANDA. The commercial benefit is greater formulation flexibility, although the clinical and regulatory burden is also higher.

What is the Orange Book status of Stimate?

Stimate is associated with NDA 020808 in FDA product records.[1] The available FDA product and labeling records do not identify a current, commercially meaningful period of regulatory exclusivity that would independently block development of a competing desmopressin nasal spray.[5]

The practical barriers are more likely to involve:

• Reference-product selection
• Bioequivalence or bridging requirements
• Device equivalence
• Product availability for comparative testing
• Quality-system remediation
• Dose uniformity
• Clinical safety related to hyponatremia

A sponsor should not assume that the absence of current listed exclusivity eliminates all intellectual-property risk. Relevant claims could exist outside the Orange Book in formulation, device, manufacturing, packaging, or use patents.

What patents protect Stimate and when does exclusivity expire?

The original active ingredient, desmopressin, is an old peptide drug. Core composition-of-matter protection is not a current barrier to market entry. The more relevant patent categories are:

Patent category	Likely commercial relevance
Desmopressin composition	Low for current entry
Aqueous nasal formulation	Moderate if claims remain enforceable
Preservative system	Moderate
Metered-dose pump	Moderate to high
Unit-dose packaging	Moderate
Stability or manufacturing process	Moderate
Method of treating von Willebrand disease	Potentially relevant, subject to claim scope
Pediatric or dosing regimen	Potentially relevant but narrower

No current Stimate-specific patent number, enforceable expiration date, or active Orange Book patent listing is established by the FDA labeling and product records cited here. A commercial diligence review should distinguish FDA-listed patents from broader U.S. and foreign patent families.

Are Paragraph IV challenges likely?

A Paragraph IV certification could arise if an ANDA applicant identifies listed patents for the reference product. Based on the available FDA records, the key risk is not a known active Orange Book patent blocking Stimate competition. The more likely dispute areas are:

• Whether a new product is sufficiently different to avoid infringement
• Pump and dose-metering claims
• Preservative-free packaging claims
• Stability and manufacturing claims
• Method-of-use claims covering bleeding control

A sponsor developing a new device or unit-dose container should conduct a freedom-to-operate review independent of the Orange Book.

What patent strategy could protect a new Stimate product?

Excipient-only claims are generally vulnerable to design-around. Stronger protection would combine the excipient system with measurable performance or clinical advantages.

Potential claim categories include:

1. A desmopressin nasal formulation within a defined pH, buffer, tonicity, and preservative range.
2. A formulation with specified impurity limits after accelerated or long-term storage.
3. A preservative-free unit-dose container delivering 150 micrograms within a defined dose-uniformity range.
4. A nasal pump engineered to control plume geometry and delivered volume.
5. A container-closure system that reduces peptide adsorption or extractables.
6. A manufacturing process that controls concentration gradients, filling accuracy, or peptide degradation.
7. A dosing regimen linked to measured clinical response and sodium monitoring.

The strongest estate would cover formulation, device, process, and use while avoiding unnecessary dependence on one excipient.

Which companies could challenge or compete with Stimate?

Direct competition would come from manufacturers of desmopressin products and from therapies used for the same bleeding disorders.

Competitor or alternative	Active ingredient or class	Commercial relevance
Generic desmopressin tablets	Desmopressin	Lower-cost systemic alternative, but not a direct nasal substitute
Desmopressin injection	Desmopressin	Hospital and procedural use
DDAVP-branded products	Desmopressin	Established physician familiarity
Humate-P	Plasma-derived factor VIII/vWF	Alternative for von Willebrand disease
Wilate	Plasma-derived factor VIII/vWF	Alternative replacement therapy
Vonvendi	Recombinant von Willebrand factor	Higher-cost non-desmopressin option
Tranexamic acid	Antifibrinolytic	Adjunct or alternative for selected bleeding episodes

A reformulated Stimate product would compete on rapid onset, outpatient convenience, predictable dosing, and lower treatment burden. It would compete against factor replacement on cost, ease of use, and suitability for responsive patients.

What commercial opportunities exist for Stimate excipients and delivery systems?

The most attractive opportunities are product-enabling rather than bulk excipient sales.

Preservative-free nasal delivery

A preservative-free product could support premium pricing and institutional adoption. The main value would come from the integrated package, including unit-dose filling, sterile or controlled manufacturing, contamination protection, and reliable dose delivery.

Improved nasal tolerability

A formulation with reduced benzalkonium chloride exposure, optimized pH, or modified tonicity could target patients who experience nasal irritation. The clinical claim would require controlled tolerability data and could support lifecycle differentiation.

Pediatric and caregiver-focused packaging

A redesigned actuator could reduce the risk of incorrect priming or repeated sprays. Dose counters, lockout mechanisms, color coding, and child-resistant packaging could improve use without changing the active ingredient.

Specialty pharmacy and hospital supply

A reliable product could address hematology clinics, emergency departments, home infusion providers, and specialty pharmacies. Supply continuity would be a meaningful commercial differentiator after the product’s recall history.

Geographic expansion

The United States is the most important market because of the FDA-approved indication and the historic Stimate brand. Europe, Canada, Japan, and selected emerging markets may offer opportunities, but regulatory requirements, reference-product availability, device standards, and local reimbursement would differ. A global strategy should use a common formulation platform with region-specific packaging and labeling.

What manufacturing barriers affect generic or reformulated Stimate entry?

The main manufacturing risks are not raw-material availability. They are process control and product performance.

Critical controls include:

• Accurate peptide weighing and solution preparation
• Uniform mixing at low concentration
• Control of pH and ionic strength
• Low adsorption during transfer and filling
• Pump calibration
• Container-closure integrity
• Preservative distribution
• Microbial control
• Stability-indicating analytical methods
• Delivered-dose testing through the full container life

A sponsor that treats Stimate as a conventional aqueous generic may underestimate the device and peptide-manufacturing risks. The 2020 recall increases the expected scrutiny of process validation, release testing, stability data, and continued process verification.

How strong is the commercial opportunity for a new Stimate product?

The opportunity is clinically focused and niche rather than mass-market. Demand is supported by the need for rapid outpatient treatment in selected hemophilia A and von Willebrand disease patients. Market size is limited by response variability, contraindications, fluid-management requirements, and competition from factor replacement products.

The most defensible commercial proposition would be:

• A validated 150-microgram dose
• Reliable nasal delivery across the container life
• Preservative-free or low-preservative positioning
• Clear sodium-monitoring instructions
• Pediatric-friendly administration
• Strong supply continuity
• Specialty hematology distribution

Public company disclosures do not separately quantify Stimate revenue exposure. Revenue estimates should therefore be built from patient prevalence, treatment frequency, responder rates, payer coverage, and expected share against desmopressin and factor replacement alternatives.

Key Takeaways

• Stimate is a 150-microgram desmopressin acetate nasal spray associated with NDA 020808.
• Its labeled excipients are citric acid, sodium citrate, sodium chloride, benzalkonium chloride, and purified water.
• The principal formulation opportunity is a preservative-free or lower-preservative nasal system with improved dose uniformity.
• Device performance and manufacturing controls are as important as excipient selection.
• The 2020 recall created a commercial opening for a reliable reformulated product.
• A 505(b)(2) strategy may provide more flexibility than an ANDA for a materially changed formulation or device.
• Core desmopressin exclusivity is not the principal barrier to entry.
• The strongest patent strategy would combine formulation, device, process, packaging, and method-of-use claims.
• The commercial market is specialized, with competition from oral and injectable desmopressin, plasma-derived products, recombinant von Willebrand factor, and antifibrinolytics.

FAQs

Can benzalkonium chloride be removed from Stimate?

Yes, but removal would require a redesigned container and preservation strategy, such as unit-dose packaging or a validated antimicrobial system. The sponsor would need to establish microbial control, stability, nasal tolerability, and delivered-dose performance.

Could a new Stimate product receive three years of FDA exclusivity?

A qualifying 505(b)(2) application with new clinical investigations essential to approval could potentially receive three years of approval exclusivity. The outcome would depend on the regulatory pathway and the nature of the supporting studies.

Is a desmopressin nasal spray eligible for generic substitution?

Potentially, if an ANDA applicant demonstrates pharmaceutical equivalence, bioequivalence, device performance, and therapeutic equivalence to the applicable reference product. A materially different formulation or device may require a 505(b)(2) application instead.

What is the highest-value excipient innovation for Stimate?

A preservative-free unit-dose system is likely the highest-value excipient and packaging innovation because it can improve tolerability, reduce contamination concerns, and create a differentiated product profile.

Can a Stimate reformulation claim orphan-drug exclusivity?

A reformulation would not automatically qualify for orphan-drug exclusivity. Orphan designation and exclusivity require satisfaction of FDA criteria, including the applicable disease-prevalence or eligibility requirements and clinical superiority considerations where relevant.

References

1. U.S. Food and Drug Administration. (2020). Stimate nasal spray prescribing information, NDA 020808.
2. U.S. Food and Drug Administration. (2020). Ferring Pharmaceuticals issues nationwide voluntary recall of Stimate nasal spray due to superpotency.
3. DailyMed. (2020). Stimate: Desmopressin acetate nasal spray, 1.5 mg/mL. National Library of Medicine.
4. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2).
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.